Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Anthera Pharmaceuticals Inc (ANTH): Biotechnology Value Fund Reports 9.99% Stake

Mark Lampert‘s Biotechnology Value Fund recently filed a Form 13G with the SEC, in which it reported acquiring 4.58 million shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH), which amass 9.99% of the company’s outstanding stock. The acquisition represents a new addition to Biotechnology Value Fund’s portfolio.

Anthera Pharmaceuticals is a biopharmaceutical company engaged in discovering and producing a variety of therapeutics to treat severe disorders. The company has two product candidates in development, and it recently reported a positive DSMB review from its Phase 3 SOLUTION Study of Sollupra™. Since the beginning of the year, the company’s stock has lost 34.05%.



Out of the 749 hedge funds followed by Insider Monkey which filed 13Fs for the June 30 reporting period, nine investors were long Anthera Pharmaceuticals (NASDAQ:ANTH) at the end of the June quarter, down by one from the previous quarter. Some of the bullish investors contained Joseph Edelman’s Perceptive Advisors, which held a position worth $4.61 million, Kevin Kotler’s Broadfin Capital, with a position valued at $3.57 million, Kris Jenner, Gordon Bussard, Graham Mcphail’s Rock Springs Capital Management, Charles Davidson’s Wexford Capital, and Hal Mintz’ Sabby Capital.

Follow Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
Trade (NASDAQ:ANTH) Now!

An investor who dumped Anthera Pharmaceuticals (NASDAQ:ANTH) during the quarter was Howard Guberman’s Gruss Asset Management, which sold a position valued, at the end of March, at $2.56 million.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Trading Fund OS 0 0 0 0 0 0%
BVF Partners OS Ltd 0 0 0 0 0 0%
BVF Partners 0 4,582,033 0 4,582,033 4,582,033 9.99%
BVF Inc 0 4,582,033 0 4,582,033 4,582,033 9.99%
Mark N. Lampert 0 4,582,033 0 4,582,033 4,582,033 9.99%
Mark Lampert
Mark Lampert
Biotechnology Value Fund / BVF Inc

Page 1 of 14 – SEC Filing

Washington, D.C. 20549
(Rule 13d-102)


(Amendment No.   )1
Anthera Pharmaceuticals, Inc.
 (Name of Issuer)
Common Stock, $0.001 par value
 (Title of Class of Securities)
03674U 20 1
 (CUSIP Number)
September 6, 2016
 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   o  Rule 13d-1(b)
   x  Rule 13d-1(c)
   o  Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
      The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
Trade (NASDAQ:ANTH) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.